United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase AuthorizationBusiness Wire · 2 days ago
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026Business Wire · 3 days ago
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production FacilityBusiness Wire · 4 days ago
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company StockDefense World · 4 days ago
United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPDBusiness Wire · 5 days ago
United Therapeutics (NASDAQ:UTHR) CEO Sells $5,129,905.00 in StockDefense World · 6 days agoUnited Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | $6.86 | $7.27 | Beat |
| May 6, 2026 | $7.00 | $5.82 | Miss |
| Feb 25, 2026 | $7.13 | $7.70 | Beat |
| Oct 29, 2025 | $6.89 | $7.16 | Beat |
| Jul 30, 2025 | $7.29 | $6.41 | Miss |
| Apr 30, 2025 | $6.29 | $6.63 | Beat |